Abstract
Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Current Neuropharmacology
Title: The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice
Volume: 9 Issue: 1
Author(s): Y. Takamatsu, H. Yamamoto, Y. Hagino, A. Markou and K. Ikeda
Affiliation:
Keywords: Conditioned place preference, Fluvoxamine, Methamphetamine, Mice, Paroxetine, Serotonin transporter, dopamine transporter, Knoutout mice, Biochemical Down Regulation
Abstract: Monoamine transporters are the main targets of methamphetamine (METH). Recently, we showed that fluoxetine, a selective serotonin reuptake inhibitor (SSRI), decreased METH conditioned place preference (CPP), suggesting that serotonin transporter (SERT) inhibition reduces the rewarding effects of METH. To further test this hypothesis, in the present study we investigated the effects of additional SSRIs, paroxetine and fluvoxamine, on METH CPP in C57BL/6J mice. In the CPP test, pretreatment with 20 mg/kg paroxetine abolished the CPP for METH, whereas pretreatment with 100 mg/kg fluvoxamine prior to administration of METH failed to inhibit METH CPP. These results suggest that paroxetine, a medication widely used to treat depression, may be a useful tool for treating METH dependence. Further, these data suggest that molecules other than the SERT [such as G protein-activated inwardly rectifying K+ (GIRK) channels] whose activities are modulated by paroxetine and fluoxetine, but not by fluvoxamine, are involved in reducing METH CPP by paroxetine and fluoxetine.
Export Options
About this article
Cite this article as:
Takamatsu Y., Yamamoto H., Hagino Y., Markou A. and Ikeda K., The Selective Serotonin Reuptake Inhibitor Paroxetine, but not Fluvoxamine, Decreases Methamphetamine Conditioned Place Preference in Mice, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017236
DOI https://dx.doi.org/10.2174/157015911795017236 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Tetrahydrobiopterin Biosynthesis, Utilization and Pharmacological Effects
Current Drug Metabolism Vaccination in Pregnancy
Current Pharmaceutical Biotechnology Implication of Oncogenic Signaling Pathways as a Treatment Strategy for Neurodegenerative Disorders – Contemporary Approaches
CNS & Neurological Disorders - Drug Targets Molecular Mechanism of a Specific NLRP3 Inhibitor to Alleviate Seizure Severity Induced by Pentylenetetrazole
Current Molecular Pharmacology Blocking Receptor Protein Tyrosine Phosphatase β /ζ: A Potential Therapeutic Strategy for Parkinsons Disease
Current Medicinal Chemistry Brain Proton Magnetic Resonance Spectroscopy: A Review of Main Metabolites and its Clinical Applications in Gliomas
Current Molecular Imaging (Discontinued) Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews Gender Bias in Acute Coronary Syndromes
Current Vascular Pharmacology Prevention and Treatment of Alzheimer Disease and Aging: Antioxidants
Mini-Reviews in Medicinal Chemistry A Synthetic Overview of New Molecules with 5-HT1A Binding Affinities
Mini-Reviews in Medicinal Chemistry Ferric Cycle Activity and Alzheimer Disease
Current Neurovascular Research Helicobacter pylori Eradication Improves the Malnutrition, Inflammation and Atherosclerosis Syndrome in Peritoneal Dialysis Patients
Vascular Disease Prevention (Discontinued) Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development
Current Medicinal Chemistry L-Carnitine - Metabolic Functions and Meaning in Humans Life
Current Drug Metabolism Effects of Ranolazine on Cardiovascular System
Recent Patents on Cardiovascular Drug Discovery A Novel High Throughput 1536-Well Notch1 γ -Secretase AlphaLISA Assay
Combinatorial Chemistry & High Throughput Screening Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Nano Era of Dentistry-An Update
Current Drug Delivery Genome-Wide Expression Analysis of Valproate Action: A Systems Level Synthesis
Current Psychopharmacology